Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma

Blood (2016) 128 (22): 4202.

https://doi.org/10.1182/blood.V128.22.4202.4202

Published: 2016

Journal Articles

IGH -Mediated Translocations, Recurrent in Classic Hodgkin Lymphoma, Frequently Correlate with an Aggressive Behavior

Iwona Wlodarska, PhD, Daan Dierickx, MD PhD, Ursula Pluys, Kathleen Doms, Carlos Graux, MD PhD, Achiel Van Hoof, MD PhD, Peter Vandenberghe, MD PhD, Lucienne Michaux, MD PhD, Thomas Tousseyn

Blood (2016) 128 (22): 2922.

https://doi.org/10.1182/blood.V128.22.2922.2922

Published: 2016

Journal Articles

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

Kerry J. Savage, MD MSc, Steven M. Horwitz, MD, Pier Luigi Zinzani, MD, PhD, Achiel Van Hoof, Sarit E. Assouline, MD, Gajanan Bhat, Mi Rim Choi, Lee F Allen, Dina Ben-Yehuda, MD, Wojciech Jurczak, Tamas Masszi, MD, Andrei R. Shustov, MD

Blood (2014) 124 (21): 3075.

https://doi.org/10.1182/blood.V124.21.3075.3075

Published: 2014

Journal Articles

Evaluation of Schistocyte Analysis By a Novel Automated Digital Cell Morphology Application

Anne-Sophie Hervent, Maaike Godefroid, Barbara Cauwelier, PhD, Achiel Van Hoof, Johan Billiet, MD, Jan Emmerechts

Blood (2014) 124 (21): 4878.

https://doi.org/10.1182/blood.V124.21.4878.4878

Published: 2014

Journal Articles

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

Andre Goy, MD, Michael E. Williams, MD, ScM, Sevgi Kalayoglu Besisik, MD, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M Rowe, MD, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, Lei Zhang, Sherri Cicero, Tommy Fu, Carla Heise, PhD, Thomas E Witzig, MD

Blood (2013) 122 (21): 3057.

https://doi.org/10.1182/blood.V122.21.3057.3057

Published: 2013

Journal Articles

Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party

Kristin Horstmann, Ariane Boumendil, PhD, Herve Finel, Jane F. Apperley, MBChB, FRCP, FRCPath, Fabio Ciceri, MD, Juergen Finke, MD, Achiel Van Hoof, Norbert Ifrah, MD, Slawomira Kyrcz-Krzemien, MD, Gustavo Milone, Ghulam J Mufti, FRCP, FRCPath, Elizabeth Naparstek, MD, Reuven Or, MD, Nigel H Russell, MD, Peter Dreger, MD

Blood (2013) 122 (21): 4632.

https://doi.org/10.1182/blood.V122.21.4632.4632

Published: 2013

Journal Articles

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte

Richard Delarue, Corinne Haioun, Vincent Ribrag, Pauline Brice, Alain Delmer, Herve Tilly, Gilles Salles, Achiel Van Hoof, Olivier Casasnovas, Nicole Brousse, Francois Lefrere, Olivier Hermine

Blood (2013) 121 (1): 48–53.

https://doi.org/10.1182/blood-2011-09-370320

Published: 2013

Includes: Supplemental data

Journal Articles

Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma

Christophe Fruchart, MD, Josette Briere, MD, Renaud Ciappuccini, MD, Olivier Casasnovas, MD, Herve Tilly, MD, Franck Morschhauser, Catherine Sebban, MD, Gilles Salles, MD, Christophe Ferme, MD, Achiel Van Hoof, Dominique Bordessoule, Reda Bouabdallah, MD, Alain Delmer, MD, Christian Gisselbrecht, MD

Blood (2012) 120 (21): 812.

https://doi.org/10.1182/blood.V120.21.812.812

Published: 2012

Journal Articles

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Blood (2012) 120 (21): 57.

https://doi.org/10.1182/blood.V120.21.57.57

Published: 2012

Journal Articles

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Andre Goy, MD, Rajni Sinha, MD, MRCP, Michael E. Williams, M.D., Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M. Rowe, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, MD, PhD, Lei Zhang, MD, Sherri Cicero, Tommy Fu, Thomas E. Witzig, MD

Blood (2012) 120 (21): 905.

https://doi.org/10.1182/blood.V120.21.905.905

Published: 2012

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

Journal Articles

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Anton Hagenbeek, MD, PhD, John Radford, MD, Achiel Van Hoof, MD, Umberto Vitolo, MD, Ama Z.S. Rohatiner, MD, Gilles Salles, MD, PhD, Pierre Soubeyran, MD, PhD, Herve Tilly, MD, Angelika Bischof Delaloye, MD, Wim L.J. van Putten, MSc, Franck Morschhauser, MD, PhD

Blood (2010) 116 (21): 594.

https://doi.org/10.1182/blood.V116.21.594.594

Published: 2010

Journal Articles

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

Eva Hoster, Bernd Metzner, Roswitha Forstpointner, Michael Pfreundschuh, Lorenz Trümper, Michael Hallek, Bernhard Wörmann, Ulrich Dührsen, MD, Christian Gisselbrecht, Hanneke C. Kluin-Nelemans, Achiel Van Hoof, Michael Unterhalt, Wolfgang Hiddemann, Martin H. Dreyling

Blood (2009) 114 (22): 880.

https://doi.org/10.1182/blood.V114.22.880.880

Published: 2009

Journal Articles

Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort.

Eva Hoster, Joerg Hasford, Olivier Hermine, Hanneke C. Kluin-Nelemans, Jan Walewski, Marek Trneny, Christian H. Geisler, Vincent Ribrag, Achiel Van Hoof, Wolfram Klapper, Wolfgang Hiddemann, Martin H. Dreyling, Michael Unterhalt

Blood (2009) 114 (22): 138.

https://doi.org/10.1182/blood.V114.22.138.138

Published: 2009

Journal Articles

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Martin H. Dreyling, MD, Eva Hoster, PhD, Achiel Van Hoof, Bernd Metzner, Christian Gisselbrecht, Michael Pfreundschuh, MD, PhD, Marcel Reiser, Lorenz H. Truemper, MD, PhD, Hjalmar Steinhauer, Jean-Michel Boiron, MD, PhD, Marc Boogaerts, MD, PhD, Vittorio Silingardi, J.C. Kluin- Nelemans, MD, PhD, Michael Unterhalt, Wolfgang Hiddemann

Blood (2008) 112 (11): 769.

https://doi.org/10.1182/blood.V112.11.769.769

Published: 2008

Journal Articles

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

Franck Morschhauser, Angelika Bischof-Delaloye, Ama Z S Rohatiner, MD, Gilles Andre Salles, MD, PhD, Jens Kuhlmann, Willem JL Van Putten, John Radford, Pierre Soubeyran, Achiel Van Hoof, Anton Hagenbeek

Blood (2008) 112 (11): 2002.

https://doi.org/10.1182/blood.V112.11.2002.2002

Published: 2008

Journal Articles

RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA

Richard Delarue, Corinne Haioun, Vincent Ribrag, Pauline Brice, Alain Delmer, Herve Tilly, Gilles Salles, Achiel Van Hoof, Olivier Casasnovas, Nicole Brousse, Francois Lefrere, Olivier Hermine

Blood (2008) 112 (11): 581.

https://doi.org/10.1182/blood.V112.11.581.581

Published: 2008

Journal Articles

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Blood (2008) 111 (2): 558–565.

https://doi.org/10.1182/blood-2007-06-095331

Published: 2008

Includes: Supplemental data

Journal Articles

Results of Haploidentical Stem Cell Transplantation after a Conditioning Regimen without Total Body Irradiation in Elderly Patients with Advanced Myeloid and Lymphoid Malignancies.

Dominik L.D. Selleslag, MD, Melanny Hidajat, M.D., Jan Van Droogenbroeck, M.D., Achiel Van Hoof, M.D., Johan Billiet, M.D, Dimitri Dehenau, Ph., Friedel Nollet, Ph.D., Arnold Criel, M.D., Ph.D.

Blood (2007) 110 (11): 3074.

https://doi.org/10.1182/blood.V110.11.3074.3074

Published: 2007

NARROW

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

A Phase II LYSA Study of Obinutuzumab Combined with Lenalidomide for Relapsed or Refractory Aggressive B-Cell Lymphoma

IGH -Mediated Translocations, Recurrent in Classic Hodgkin Lymphoma, Frequently Correlate with an Aggressive Behavior

Safe and Effective Treatment of Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) and Low Baseline Platelet Counts with Belinostat

Evaluation of Schistocyte Analysis By a Novel Automated Digital Cell Morphology Application

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

Second Allogeneic Stem Cell Transplantation (AlloSCT) In Patients With Relapsed Lymphoma After First Allosct. A Retrospective Study Of The EBMT Lymphoma Working Party

CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte

Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma

First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

Autologous Stem Cell Transplantation and Addition of Rituximab Independently Prolong Response Duration in Advanced Stage Mantle Cell Lymphoma.

Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort.

Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the

Extended Follow-up of the International Randomized Phase 3 First-Line Indolent Trial (FIT) Shows Durable Benefit of 90 Y-Ibritumomab Tiuxetan (Zevalin®) Consolidation of First Remission in Advanced Stage Follicular Non-Hodgkin’s Lymphoma.

RCHOP and RDHAP Followed by Autologous Stem Cell Transplantation (ASCT) in Mantle Cell Lymphoma (MCL) : Final Results of a Phase II Study from the GELA

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Results of Haploidentical Stem Cell Transplantation after a Conditioning Regimen without Total Body Irradiation in Elderly Patients with Advanced Myeloid and Lymphoid Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only